22 -9 (81) 2025 - Shakhanova Sh.Sh. Rakhimov N.M. - INNOVATIVE QUESTIONNAIRE CASAQ V2.0: COMPREHENSIVE ASSESSMENT OF SARCOPENIA WITH CONSIDERATION OF BIOMARKERS AND CLINICAL FACTORS

INNOVATIVE QUESTIONNAIRE CASAQ V2.0: COMPREHENSIVE ASSESSMENT OF SARCOPENIA WITH CONSIDERATION OF BIOMARKERS AND CLINICAL FACTORS

Pulatov O.K. - Samarkand State Medical University

Rakhimov N.M. - Samarkand Regional Interregional Hospice

Tillyashaykhov M.N. - Republican Specialized Scientific and Practical Medical Center of Oncology and Radiology

Boyko E.V. - Republican Specialized Scientific and Practical Medical Center of Oncology and Radiology

Resume

Sarcopenia in oncology patients is a complex multidomain syndrome characterized by the decline of muscle mass, strength, and physical function, which is aggravated by systemic inflammation and nutritional disorders. Traditionally applied questionnaires for sarcopenia screening (SARC-F, SARC-CalF, MSRA, Ishii Score, ECOG/Karnofsky) have several limitations: low sensitivity, subjectivity, and the lack of adaptation to the specific features of oncology patients. This study presents an innovative CANCER-ASSOCIATED SARCOPENIA ASSESSMENT QUESTIONNAIRE (CASAQ) – version 2.0, which integrates both subjective and objective indicators, as well as new laboratory biomarkers (IL-6, CRP, albumin, etc.). CASAQ v2.0 provides more accurate diagnosis, risk stratification, and personalized management strategies for patients, which makes it highly clinically and prognostically significant.

Keywords: sarcopenia, oncology patients, screening, CASAQ v2.0, biomarkers, systemic inflammation, diagnostics, prognostic model.

First page

131

Last page

138

For citation:Shakhanova Sh.Sh. Rakhimov N.M. Tillyashaykhov M.N. Boyko E.V. - INNOVATIVE QUESTIONNAIRE CASAQ V2.0: COMPREHENSIVE ASSESSMENT OF SARCOPENIA WITH CONSIDERATION OF BIOMARKERS AND CLINICAL FACTORS//New Day in Medicine 9(83)2025 131-138 https://newdayworldmedicine.com/en/new_day_medicine/9-83-2025

List of References

1. Cruz-Jentoft AJ, Bahat G, Bauer J, et al. Sarcopenia: revised European consensus on definition and diagnosis. // Age Ageing. 2019;48(1):16–31.
2. Prado CM, Lieffers JR, McCargar LJ, et al. Prevalence and clinical implications of sarcopenic obesity in patients with solid tumours of the respiratory and gastrointestinal tracts: a population-based study. // Lancet Oncol. 2008;9(7):629–635.
3. Shachar SS, Williams GR, Muss HB, Nishijima TF. Prognostic value of sarcopenia in adults with solid tumours: a meta-analysis and systematic review. // Eur J Cancer. 2016;57:58–67.
4. Pamoukdjian F, Bouillet T, Levy V, et al. Prevalence and predictive value of pre-therapeutic sarcopenia in cancer patients: a systematic review. // Clin Nutr. 2018;37(4):1101–1113.
5. Baracos VE, Martin L, Korc M, et al. Cancer-associated cachexia. Nat Rev Dis Primers. 2020;6:24.
6. Malmstrom TK, Morley JE. SARC-F: a simple questionnaire to rapidly diagnose sarcopenia. // J Am Med Dir Assoc. 2013;14(8):531–532.
7. Barbosa-Silva TG, Menezes AMB, Bielemann RM, et al. Enhancing SARC-F: improving sarcopenia screening in the clinical practice. // J Am Med Dir Assoc. 2016;17(12):1136–1141.
8. Ida S, Kaneko R, Murata K. Validation of the Japanese version of the SARC-F questionnaire to assess sarcopenia in older adults. // Geriatr Gerontol Int. 2017;17(5):743–749
9. Шаханова Ш. Шахноза, Рахимов М. Нодир. Аспекты синдрома саркопении в онкологической практике: диагностика и лечение (обзор литературы) // Журнал биомедицины и практики. 2023;8(3):406-417.

   file

   download